US equities
|
SPCX
$168.41
▲+5.94%
NVDA
$237.34
▲+1.45%
MU
$1,066.79
▼-0.75%
TSLA
$378.90
▲+2.24%
MSFT
$525.60
▲+1.56%
SNDK
$1,715.00
▼-0.29%
INTC
$117.23
▼-1.76%
META
$743.38
▲+2.10%
SPCX
$168.41
▲+5.94%
NVDA
$237.34
▲+1.45%
MU
$1,066.79
▼-0.75%
TSLA
$378.90
▲+2.24%
MSFT
$525.60
▲+1.56%
SNDK
$1,715.00
▼-0.29%
INTC
$117.23
▼-1.76%
META
$743.38
▲+2.10%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Monopar Therapeutics Inc. - Common Stock
(NQ:
MNPR
)
78.89
+0.92 (+1.17%)
Delayed Quote
Updated: 1:14 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Monopar Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
August 19, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 12, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
July 22, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
July 20, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
June 30, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
June 26, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
June 01, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
May 19, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
April 19, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
March 27, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
March 02, 2026
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
↗
November 14, 2025
Via
Benzinga
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
November 13, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
November 09, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
October 15, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
October 13, 2025
Via
Benzinga
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
↗
September 25, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
September 23, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
September 23, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout
↗
September 15, 2025
The company is working on a treatment for a rare, inherited disease that causes copper to build up in the body.
Via
Investor's Business Daily
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
September 03, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
September 14, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
August 12, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
June 23, 2025
Via
Benzinga
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
June 11, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
June 03, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
May 13, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
May 07, 2025
From
Monopar Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
